Abcuro
Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases
$66MSeries D
Role not disclosedLoading investors…
Loading investors…
Activity from announced rounds
Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases
Makes organ preservation and perfusion technology for liver transplants
Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout
Develops medicines targeting historically undruggable protein targets in cancer